Research Topics
Genomes and GenesSpecies | Charles FrancisSummaryAffiliation: University of Rochester Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Ultrasound-enhanced thrombolysisC W Francis
Vascular Medicine Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Echocardiography 18:239-46. 2001..These studies form the basis for clinical trials investigating the potential of ultrasound as an adjunct to improve thrombolytic therapy...- Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patientsCharles W Francis
Department of Hematology and Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
N Engl J Med 356:1438-44. 2007 - Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacementCharles W Francis
Department of Medicine, University of Rochester, Rochester, NY, USA
N Engl J Med 349:1703-12. 2003..The purpose of the present study was to determine whether a higher dose of ximelagatran is superior to warfarin... - Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillationC W Francis
Hematology Oncology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
Curr Pharm Des 11:3931-41. 2005..The oral direct thrombin inhibitor, ximelagatran, shows promise in providing simplified, effective therapy for venous thromboembolism and atrial fibrillation... - Ximelagatran: a new oral anticoagulantCharles W Francis
Hematology Oncology Unit, School of Medicine and Dentistry, University of Rochester, 601 Elmwood Avenue, Box 610, Rochester, NY, USA
Best Pract Res Clin Haematol 17:139-52. 2004..Ximelagatran may be an alternative oral anticoagulant for patients currently taking vitamin K antagonists... - Factor XIII polymorphisms and venous thromboembolismCharles W Francis
Vascular Medicine Unit, University of Rochester School of Medicine and Dentistry, NY, USA
Arch Pathol Lab Med 126:1391-3. 2002..To review the relationship between factor XIII polymorphisms and venous thromboembolism... - Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trialCharles W Francis
University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Ann Intern Med 137:648-55. 2002..Ximelagatran, an oral direct thrombin inhibitor, has shown promising efficacy and tolerability in patients undergoing total hip or knee arthroplasty... 
Prevention of venous thromboembolism in hospitalized patients with cancerCharles W Francis
Department of Medicine, University of Rochester, Rochester, NY, USA
J Clin Oncol 27:4874-80. 2009..In conclusion, most patients hospitalized with cancer are at high risk of venous thromboembolism, and thromboprophylaxis should be provided in the absence of active bleeding or a high bleeding risk...- Ultrasound and thrombolysisC W Francis
Department of Medicine, University of Rochester School of Medicine and Dentistry, NY, USA
Vasc Med 6:181-7. 2001..The use of ultrasound to mechanically disrupt occlusive thrombi or to accelerate enzymatic thrombolysis offers a new approach to treating occlusive thrombotic disease... - Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulationJ T Horan
Hematology Unit, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Semin Thromb Hemost 27:657-66. 2001..Serial monitoring of soluble fibrin or D-dimer assays may be of value in evaluating the response to therapy and possibly in identifying at-risk patients... - Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational studyAlok A Khorana
James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, New York, USA
Cancer 104:2822-9. 2005..The incidence of venous thromboembolism (VTE) is increased in cancer, but little information is available about risk factors in cancer patients on chemotherapy... - Plasminogen activator inhibitor-1 levels and polymorphismsCharles W Francis
Vascular Medicine Unit, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
Arch Pathol Lab Med 126:1401-4. 2002..To review the published evidence of a relationship between levels of plasminogen activator inhibitor-1 (PAI-1) or the 4G/5G polymorphism of the PAI-1 gene and the occurrence of venous thromboembolic disease... 
Heparin induced thrombocytopenia and thrombosis in a tertiary care hospitalMakiko Ban-Hoefen
Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA
Thromb Res 124:189-92. 2009..The diagnosis depends on a combination of both the clinical presentation and laboratory detection of an appropriate antibody...- Thromboembolism in hospitalized neutropenic cancer patientsAlok A Khorana
James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
J Clin Oncol 24:484-90. 2006..We investigated venous and arterial thromboembolism and associated outcomes in hospitalized cancer patients actively receiving therapy, as identified by neutropenia... - Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancerAlok A Khorana
James P Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, New York 14642, USA
Clin Cancer Res 13:2870-5. 2007..We correlated TF expression with vascular endothelial growth factor (VEGF) expression, microvessel density, and venous thromboembolism in resected pancreatic cancer... - A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complicationsNicole M Kuderer
James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
Cancer 110:1149-61. 2007.... - Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patientsAlok A Khorana
James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, New York 14642, USA
Cancer 110:2339-46. 2007..In the current study, the frequency, risk factors, and trends associated with VTE were examined among hospitalized cancer patients... - Development and validation of a predictive model for chemotherapy-associated thrombosisAlok A Khorana
James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, NY, USA
Blood 111:4902-7. 2008..5 months (C-statistic = 0.7 for both cohorts). This model can identify patients with a nearly 7% short-term risk of symptomatic VTE and may be used to select cancer outpatients for studies of thromboprophylaxis... - Blood transfusions, thrombosis, and mortality in hospitalized patients with cancerAlok A Khorana
James P Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, New York, USA
Arch Intern Med 168:2377-81. 2008..Anemia is frequent in patients with cancer, but there are concerns regarding treatment with erythropoiesis-stimulating agents. Blood transfusions are commonly used as an alternative, but with little data regarding outcomes... - Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray studyJorge L Yao
Pathology, University of Rochester Medical Center, Rochester, NY 14642, USA jorge
Cancer Invest 27:430-4. 2009..001). Our findings reinforce the link between angiogenesis and TF expression in PCa. We suggest further exploration of TF-mediated pathways leading to increased tumor aggressiveness in PCa, and the possible use of anti-TF agents in PCa... - FGF-2 binding to fibrin(ogen) is required for augmented angiogenesisAbha Sahni
Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
Blood 107:126-31. 2006..These results demonstrate that binding of FGF-2 to fibrin(ogen) mediated by the 5-residue FGF-2-fibrin(ogen) interactive site is required for augmented angiogenesis... - Endothelial cell activation by IL-1beta in the presence of fibrinogen requires alphavbeta3Abha Sahni
Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
Arterioscler Thromb Vasc Biol 25:2222-7. 2005..The purpose of this study was to investigate the receptor requirements for enhanced IL-1beta-induced secretion of nitric oxide (NO) by endothelial cells (ECs) in the presence of fibrinogen... - Atherosclerotic risk genotypes and recurrent coronary events after myocardial infarctionArthur J Moss
Cardiology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Am J Cardiol 96:177-82. 2005.... - Interleukin-1beta but not IL-1alpha binds to fibrinogen and fibrin and has enhanced activity in the bound formAbha Sahni
Department of Medicine, PO Box 610, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642, USA
Blood 104:409-14. 2004..We conclude that IL-1beta binds with high affinity to fibrin(ogen) and demonstrates increased activity in the bound form... - Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires alphavbeta3Abha Sahni
Hematology Oncology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Ave, Rochester, NY, USA
Blood 104:3635-41. 2004..We conclude that fibrinogen binding of FGF-2 enhances EC proliferation through the coordinated effects of colocalized alpha(v)beta(3) and FGFR1... - Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weightAlok A Khorana
James P. Wilmot Cancer Center and Hematology/Oncology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY14642, USA
Arterioscler Thromb Vasc Biol 23:2110-5. 2003..This Mr dependence differs from that required for anticoagulant activity... - Venous thrombosis and stenosis after implantation of pacemakers and defibrillatorsGrzegorz Rozmus
Cardiology Unit of the Department of Medicine, University of Rochester Medical Center, Strong Memorial Hospital, 601 Elmwood Ave, Box 679, Rochester, NY, 14642, USA
J Interv Card Electrophysiol 13:9-19. 2005..Anticoagulant therapy (for other reasons than pacemaker lead) seemed to have protective antithrombotic effect... - Identification of a binding site on human FGF-2 for fibrinogenHu Peng
Department of Medicine, Hematology Oncology Unit, University of Rochester School of Medicine and Dentistry, 601 Elmwood Ave, Rochester, NY 14642, USA
Blood 103:2114-20. 2004..3 nM and 8.6 nM, respectively, compared with 1.3 nM for wild-type FGF-2. We conclude that these 5 residues define a high-affinity binding site in FGF-2 for fibrinogen... - Fibrinogen regulates the expression of inflammatory chemokines through NF-kappaB activation of endothelial cellsMin Guo
Hematology Oncology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
Thromb Haemost 92:858-66. 2004..From our findings, we conclude that fibrinogen regulates NF-kappaB activation and expression of inflammatory chemokines in endothelial cells and may be involved in mediating inflammatory processes... - Direct thrombin inhibitorsKaren L Kaplan
Hematology-Oncology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA
Semin Hematol 39:187-96. 2002..The chemical structure, kinetics of thrombin inhibition, pharmacokinetics, and clinical use of each of these agents are discussed... - Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticlesDenise M Ray
University of Rochester Medical Center, Environmental Medicine, Rochester, New York 14642, USA
Thromb Haemost 99:86-95. 2008.... - Foxp3 regulates megakaryopoiesis and platelet functionJamie J Bernard
Department of Environmental Medicine, University of Rochester, Rochester, NY 14642, USA
Arterioscler Thromb Vasc Biol 29:1874-82. 2009..Scurfy mice and some humans with IPEX are also thrombocytopenic. The purpose of this study was to determine whether the absence of functional Foxp3 leads to defects in megakaryocytes and platelets... - Randomized prospective study comparing routine versus selective use of sonography of the complete calf in patients with suspected deep venous thrombosisRonald H Gottlieb
Department of Radiology, University of Rochester Medical Center, 601 Elmwood Ave, Box 648, Rochester, NY 14642, USA
AJR Am J Roentgenol 180:241-5. 2003.... - American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancerGary H Lyman
Duke University Medical Center, University of Rochester Medical Center, Rochester, USA
J Clin Oncol 25:5490-505. 2007..To develop guideline recommendations for the use of anticoagulation in the prevention and treatment of venous thromboembolism (VTE) in patients with cancer... - NF-kappaB activation suppresses host cell apoptosis during Rickettsia rickettsii infection via regulatory effects on intracellular localization or levels of apoptogenic and anti-apoptotic proteinsSuresh G Joshi
Hemostasis and Thrombosis Program, Hematology-Oncology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, P.O. Box 610, 601 Elmwood Avenue, Rochester, NY 14642, USA
FEMS Microbiol Lett 234:333-41. 2004.... - Venous thromboembolism in patients with diffuse large B-cell lymphomaRami S Komrokji
Department of Medicine, University of Cincinnati and Cincinnati Veterans Administration Medical Center, Cincinnati, OH 45267 0501, USA
Leuk Lymphoma 47:1029-33. 2006..2 years (95% CI 1.8 - 8.6) for those without VTE (P = 0.038). We conclude that VTE is a frequent complication of DLBCL that occurs particularly at diagnosis and during initial therapy, and it is associated with a worse prognosis... - Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapyGregory C Connolly
James P Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, NY, USA
Thromb Res 126:113-8. 2010..Leukocytosis has been associated with thrombosis and mortality in cancer patients. We explored the association of leukocytosis with venous thromboembolism (VTE) and early mortality in cancer patients initiating chemotherapy... - 15-deoxy-delta12,14-PGJ2 enhances platelet production from megakaryocytesJamie J O'Brien
Department of Environmental Medicine and the Lung Biology and Disease Program, University of Rochester, NY, USA
Blood 112:4051-60. 2008.... - Ultrasound improves tissue perfusion in ischemic tissue through a nitric oxide dependent mechanismValentina N Suchkova
Hematology/Oncology Unit, Department of Medicine, University of Rochester Medical Center, NY 14642, USA
Thromb Haemost 88:865-70. 2002..We conclude that the application of 40 kHz at low intensity improves perfusion and reverses acidosis in acutely ischemic muscle through a nitric oxide dependent mechanism... - Ultrasound enhancement of fibrinolysis at frequencies of 27 to 100 kHzValentina Suchkova
Vascular Medicine Unit, Department of Medicine, Rochester Center for Biomedical Ultrasound, Rochester, NY 14642, USA
Ultrasound Med Biol 28:377-82. 2002..We conclude that US in the range of 27 to 100 kHz is effective in accelerating fibrinolysis at intensities and pulsing conditions that minimize the probability of heating and cavitation in clinical applications... - Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trialJean-Noel Fiessinger
Department of Vascular Medicine, , Paris, France
JAMA 293:681-9. 2005..Increased levels of liver enzymes in 9.6% of ximelagatran-treated patients require regular monitoring; the mechanism requires further evaluation. Prospective assessment of coronary events in future studies is warranted... - Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplastyClifford W Colwell
Orthopaedic Surgery, Scripps Clinic, 11025 North Torrey Pines Road, Suite 140, La Jolla, CA 92037, USA
J Bone Joint Surg Am 87:2169-77. 2005....
Research Grants
- GRADUATE TRAINING HEMATOLOGY RESEARCHCharles Francis; Fiscal Year: 2007..The program will be directed by Dr. Charles Francis, Director of the Program in Thrombosis and Hemostasis and by a Co-director, Dr...
- Venous Thrombosis in Cancer Outpatients: Prevention and Role of Tissue FactorCharles W Francis; Fiscal Year: 2010..We will also do studies to determine if certain abnormalities in the blood clotting system can help predict this problem. ..